Our Inspiration
- Living With Rare Diseases
- Real Stories
  - NF1
  - aHUS
  - gMG
  - HPP
  - LAL-D
  - NMOSD
  - PNH
- Support Services
Albie, one of our guiding stars

When Albie was born, his mom, Charlotte, said that he was “absolutely fine. Everything was fine for about two weeks.”
Our Medicines
- Conditions We Treat
  - aHUS
  - gMG
  - HPP
  - LAL-D
  - NF1 PN
  - NMOSD
  - PNH
- Medicines
Our medicines help people like Donnan

As a father of two young children, Donnan recalls being afraid of what the future would hold prior to his diagnosis.
Our Research
We innovate for Ruthie

Married with a newborn son, Ruthie was scared to learn that PNH was a life-threatening illness that at the time had no approved treatment.
Our Commitment
We give back for families like Evie's

At only three months old, Evie's parents were told that her case was severe and that there were no approved or effective treatment options.
Our Company
Roberta is our inspiration

Despite having a constant struggle with symptoms, Roberta revisited her dreams and put herself through nursing school.
Your Career
- Career Opportunities
  - Join Our Team
- Working Here
  - Benefits
  - Culture
Make a difference for families like Tristan's

Tristan's parents experienced a whirlwind of emotions and fear after learning their 5-year-old son had such a rare and serious disease.

Belgium

Alexion has operations in Belgium to serve patients locally. Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare disorders.

Careers

To find out more about career opportunities at Alexion in your country, please visit our Careers section and search for job opportunities by location.

CAREERS

Belgium

Careers

You are now leaving www.alexion.com, a website provided by Alexion Pharmaceuticals, Inc. This link will take you to a different site to which this Privacy Policy does not apply.

You are now leaving the alexion.com UK webpage for the global alexion.com website. The content on the global site is intended for a U.S. audience only